SG Americas Securities
GLUE icon

SG Americas Securities’s Monte Rosa Therapeutics GLUE Stock Holding History

SG Americas Securities’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$704K Buy
29,083
+8,615
+42% +$163K ﹤0.01% 2115
2026
Q1 		$337K Buy
20,468
+3,189
+18% +$61K ﹤0.01% 2397
2025
Q4 		$271K Buy
+17,279
New +$233K ﹤0.01% 2803
2025
Q1 		– Sell
-16,742
Closed -$116K – 3574
2024
Q4 		$116K Buy
16,742
+6,323
+61% +$47.4K ﹤0.01% 2617
2024
Q3 		$55K Buy
+10,419
New +$52.6K ﹤0.01% 3226
2024
Q1 		– Sell
-12,257
Closed -$69K – 3149
2023
Q4 		$69K Sell
12,257
-1,609
-12% -$6.31K ﹤0.01% 2861
2023
Q3 		$66K Buy
+13,866
New +$89.3K ﹤0.01% 2883
2023
Q2 		– Sell
-13,411
Closed -$104K – 2618
2023
Q1 		$104K Buy
13,411
+2,779
+26% +$19.3K ﹤0.01% 2885
2022
Q4 		$81K Buy
+10,632
New +$88.6K ﹤0.01% 2773
2022
Q3 		– Sell
-11,319
Closed -$109K – 3317
2022
Q2 		$109K Buy
+11,319
New +$114K ﹤0.01% 3073
2022
Q1 		– Sell
-6,621
Closed -$135K – 3149
2021
Q4 		$135K Sell
6,621
-617
-9% -$12.9K ﹤0.01% 2887
2021
Q3 		$161K Buy
+7,238
New +$207K ﹤0.01% 3381

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SG Americas Securities's GLUE Position: Q2 2026 in Review

SG Americas Securities increased its Monte Rosa Therapeutics (GLUE) stake by 42% in Q2 2026, buying an estimated $163K and bringing the position to 29,083 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #2115.

SG Americas Securities first reported a position in GLUE in Q3 2021 and has held it in 12 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • SG Americas Securities held 29,083 shares of Monte Rosa Therapeutics worth $704K as of Q2 2026.
  • SG Americas Securities bought 8,615 Monte Rosa Therapeutics shares in Q2 2026, an estimated $163K.
  • Monte Rosa Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2115 holding.
  • SG Americas Securities first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.